
In 2011 the total value loss from patent expirations was at 20.4 billion dollars, and in 2012 that number is expected to increase by 74 % to 35.5 billion dollars.
But while the major players in the pharmaceutical industry face great challenges because of the pipeline drought, US company CVS Caremark will actually profit from the many patent expirations.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app